Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (190${count})

  • MJFF Research Grant, 2011
    Ghrelin Concentrations in CSF and Corresponding Serum Samples in PD Patients and Controls

    Objective/Rationale:
    The aim of this study is to establish a valid method for measuring ghrelin concentrations in human cerebrospinal fluid samples. Ghrelin is an appetite-stimulating hormone with...

  • Clinical Intervention Awards, 2009
    MASTER PD: Magnetic Stimulation for the Treatment of Motor and Mood Symptoms of Parkinson's Disease: A Four-Center, Sham-Controlled, Parallel Group Study

    Objective/Rationale:
    To determine the efficacy and duration of benefit of noninvasive brain stimulation with repetitive transcranial magnetic stimulation (rTMS) to modulate brain activity in order to...

  • Edmond J. Safra Movement Disorders Research Career Development Award, 2024
    Towards a Better Understanding of Treatment-refractory Gait Issues in Parkinson’s Disease

    Study Rationale: Freezing of gait (FOG) is a sudden arrest of gait despite the intention to continue walking, often while a person is turning, walking in a confined space or is in a situation that...

  • Therapeutics Development Initiative, 2012
    Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s Disease

    Objective/Rationale:
    Fumaric acid esters have shown immuno-modulatory and neuroprotective effects in cell-based systems,  pre-clinical models of disease and clinical trials in multiple sclerosis and...

  • Therapeutics Development Initiative, 2012
    Lead Optimization for a Parkinson's Disease Therapeutic

    Objective/Rationale: 
    CuII(atsm) has the potential to delay disease progression in Parkinson’s disease, based on extensive pre-clinical model data. CuII(atsm) has been shown to significantly improve...

  • Therapeutics Development Initiative, 2011
    Testing of Ambroxol in the Thy1-Alpha-Synuclein Pre-clinical Model of Parkinson's disease

    Objective/Rationale:
    Biochemical evidence suggests that blocking the maturation of a natural enzyme, glucocerebrosidase (GCase), can cause the build-up of alpha-synuclein deposits in neurons.  Such...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.